A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is a phase III multi-centre study in three periods: the first period is a phosphate
binder washout for 4 weeks, the second period is an open-label, randomised, parallel group,
flexible dose, the third period is a placebo-controlled withdrawal comparing MCI-196 with
placebo for 4 weeks.